On Tuesday, October 22, 2024, the Association of Cannabinoid Specialists welcomed Eugene Vortsman, DO to present on Psychedelic Medicine: A Clinical Perspective.
While this is a slight departure from our regular programming, ACS feels that with psychedelics on the ballot in states such as Massachusetts in 2024, as well as the increase in research and interest, it is important to provide educational opportunities on such topics.
The presentation, hosted by Makenna Campbell and featuring Dr. Eugene Vortsman, explores the foundations of psychedelic medicine, detailing its historical, clinical, and potential therapeutic applications. Dr. Vortsman, a leader in addiction and pain management as well as psychedelic education, begins by outlining the history of substances such as LSD, psilocybin, ketamine, MDMA, DMT, and Ibogaine. He highlights their past research, regulatory challenges, and potential medical benefits, particularly in treating substance use disorders, depression, PTSD, and chronic pain conditions. The session delves into the mechanisms of these psychedelics, their therapeutic effects, and ongoing studies that seek to prove their efficacy and safety.
Dr. Vortsman further emphasizes the necessity of psychedelic-assisted therapy for achieving positive outcomes and the current landscape of FDA-approved and funded trials. A significant portion is devoted to addressing the stigma, potential side effects, and advocating for a regulated and compassionate approach to utilizing these substances in modern medicine.